April 7, 2020

Top 10 Companies Leveraging Genome Editing in 2020

Genome editing is a techniques that is used for the changing the DNA of a cell of an organism. The technique involves cutting of DNA sequences for the addition or the removal of the DNA in the genome. The targeted stakeholders for the reports include service providers, vendors, research institutes, supplier, and distributors of genome editing technologies.

The Prominent Players Operating In Genome Editing Industry Are

  • Transposagen Biopharmaceuticals, Inc.
  • Integrated DNA Technologies, Inc.
  • Thermo Fisher Scientific Inc.
  • GenScript
  • Lonza
  • Horizon Discovery Group plc
  • Sangamo Therapeutics, Inc.
  • New England Biolabs
  • Editas Medicine
  • Merck KGaA

GET FREE TRIAL OF GENOME EDITING COMPANIES INSIGHTS @ SUBSCRIBE

Industry Insight :

Rise in the Advancements for Genome Editing Technologies

The biotechnological field is characterized as a continuously developing the technologies for the betterment of the health for all the living organisms. Therefore, the technologies for the genome editing is undergoing various advancements, the most recent advancement for the genome editing is utilizing the nucleases which include the zinc finger nuclease (ZFN), transcription activators like effector nuclease (TALEN) and (clustered regulatory interspaced short palindromic repeats) CRISPR Cas9 system. The technologies has been successfully implemented in the several crops, including the Solanaceae plants, such as tomato, potato, tobacco, and petunia. CRISPR Case 9 among the three nucleases is the best for breeding, crop improvement, and the functional analysis of genes of interest. The technology is best due to its simplicity and high efficiency.

Limitations in Genome Editing

Rapid advances in biotechnology such as gene editing is likely to raise some regulatory challenges, in turn, government struggle to keep pace. According to the Worldwide Threat Assessment of the US Intelligence Community, the US National Academies of Science have organized a variety of domestic and international meetings about issued reports on the potential promises and downsides of gene editing in the US. Gene editing included in the Worldwide Threat Assessment , which was submitted in 2016 and 2017. In spite of the scientific and policy interest, In the US, there were no any published study about Crispr technology that how gene editing technologies are developing within and across specific country contexts. Moreover, gene editing research involves human embryos faces varied regulatory obstacles in certain countries. For instance, In Canada, human germline editing is now banned. Certainly, it is criminalized under the 2004 Assisted Human Reproduction Act, and punishable by fines of 500,000 Canadian dollars or up to 10 years of jail time. Recently, the Canadian Institutes of Health Research (the Canadian equivalent of the US National Institutes of Health) has challenged the law with respect to gene editing and has called for human germline gene editing to be decriminalized and legalized.

Want To Know More About

  • Scopes for the Consumer Genomics
  • Technology Insights
  • Application Insights
  • End User Insights

GET ALL BUSINESS INSIGHT ON GENOME EDITING INDUSTRY

WHY SUBSCRIBE WITH US?

Insight Library

  • One stop platform for all your market insight information needs

Monthly Subscription

  • Pay monthly subscription and access all you want. Plans start $299.

Pay as per Requirement

  • Pay as per Requirement. Affordable Product. No Compulsion for Yearly Subscription

Free Trail Access

  • 5 Day Free Trial For Limited Read Access to your Platform. Easy Trial Access. No Credit Card required

References:

  • theinsightpartners.com